Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics faces securities lawsuit
Regulatory class action lawsuit

ADMA Biologics faces securities lawsuit

Analysis based on 6 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026

Sentiment
-50
Attention
3
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against ADMA Biologics could lead to significant financial penalties and a decline in its stock price due to allegations of securities law violations. Investors who purchased ADMA Biologics securities during the Class Period may suffer losses, while Kahn Swick & Foti stands to gain from successful litigation.

Biotechnology Legal Services
Event Summary

Kahn Swick & Foti, LLC (KSF) has initiated a class action securities lawsuit against ADMA Biologics, Inc. (ADMA) on behalf of investors who purchased the company's securities between August 9, 2024, and March 25, 2026. The lawsuit, pending in the United States — United States District Court for the District of New Jersey, alleges that ADMA Biologics and its executives failed to disclose material information in their Offering Documents. Specific allegations include an undisclosed related party transaction, the use of channel stuffing to inflate revenue appearance, and a lack of adequate internal controls. KSF, with partners like Lewis Kahn and Charles Foti, is seeking to recover losses for affected investors, who have until August 10, 2026, to apply for lead plaintiff status.

Key Actions
100 ADMA Biologics issued misleading information
95 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics
Entities Involved
stock
ADMA Biologics
ADMA Biologics is the defendant in a class action securities lawsuit, facing allegations of undisclosed related party transactions, channel stuffing, and inadequate internal controls, which could lead to significant financial and reputational damages.
Importance 100 Sentiment -70
priv
Kahn Swick & Foti
Kahn Swick & Foti, a securities litigation law firm, is initiating and representing investors in the class action lawsuit against ADMA Biologics, aiming to recover losses for affected shareholders.
Importance 90 Sentiment 60
per
Lewis Kahn
Lewis Kahn is the Managing Partner of Kahn Swick & Foti and is actively involved in notifying and assisting investors regarding the class action lawsuit against ADMA Biologics.
Importance 40 Sentiment 50
per
Charles Foti
Charles Foti, a partner at Kahn Swick & Foti and former Attorney General of Louisiana, is involved in the firm's notification to investors about the class action lawsuit against ADMA Biologics.
Importance 40 Sentiment 50
govactor
United States — United States District Court for the District of New Jersey
The United States — United States District Court for the District of New Jersey is the venue where the class action securities lawsuit against ADMA Biologics is pending.
Importance 30 Sentiment 0
cnt
United States
The United States is the nation where the class action lawsuit is being filed and where the legal framework for such actions exists.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.